[HTML][HTML] Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based …
S Lorenzen, P Thuss-Patience, SE Al-Batran… - Annals of oncology, 2013 - Elsevier
Background The aim of this study was to evaluate the impact of pathologic complete
response (pCR) on outcome in patients with gastric or esophagogastric junction (EGJ) …
response (pCR) on outcome in patients with gastric or esophagogastric junction (EGJ) …
[HTML][HTML] Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines
XZ Wang, ZY Zeng, X Ye, J Sun, ZM Zhang… - World journal of …, 2020 - ncbi.nlm.nih.gov
Gastric cancer is one of the most common digestive system tumors in China, and locally
advanced gastric cancer (LAGC) accounts for a high proportion of newly diagnosed cases …
advanced gastric cancer (LAGC) accounts for a high proportion of newly diagnosed cases …
[HTML][HTML] Pattern of lymph node metastases in gastric cancer: a side-study of the multicenter LOGICA-trial
C de Jongh, L Triemstra, A van Der Veen, LAA Brosens… - Gastric Cancer, 2022 - Springer
Background The relation between gastric cancer characteristics and lymph node (LN)
metastatic patterns is not fully clear, especially following neoadjuvant chemotherapy (NAC) …
metastatic patterns is not fully clear, especially following neoadjuvant chemotherapy (NAC) …
[HTML][HTML] Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer—a multicenter study of GIRCG (Italian Research Group for Gastric …
MA Mazzei, L Di Giacomo, G Bagnacci… - … imaging in medicine …, 2021 - ncbi.nlm.nih.gov
Background To predict response to neoadjuvant chemotherapy (NAC) of gastric cancer
(GC), prior to surgery, would be pivotal to customize patient treatment. The aim of this study …
(GC), prior to surgery, would be pivotal to customize patient treatment. The aim of this study …
Prognostic significance of microsatellite‐instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy
GM Haag, E Czink, A Ahadova… - … journal of cancer, 2019 - Wiley Online Library
Perioperative systemic treatment is standard of care for Caucasian patients with locally
advanced, resectable gastric adenocarcinoma. The prognostic relevance of the …
advanced, resectable gastric adenocarcinoma. The prognostic relevance of the …
Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and …
Background Recent data suggest primary resection as the preferable approach in patients
with signet ring cell gastric cancer (SRC). The aim of our retrospective exploratory study was …
with signet ring cell gastric cancer (SRC). The aim of our retrospective exploratory study was …
[HTML][HTML] Results of the observational prospective RealFLOT study
E Giommoni, D Lavacchi, G Tirino, L Fornaro… - BMC cancer, 2021 - Springer
Abstract Background Perioperative FLOT (5-fluorouracil, oxaliplatin and docetaxel) has
recently become the gold standard treatment for fit patients with operable gastric (GC) or …
recently become the gold standard treatment for fit patients with operable gastric (GC) or …
Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer
M Zhang, H Yang, T Fu, M Meng, Y Feng… - Molecular …, 2023 - Wiley Online Library
A good response to neoadjuvant chemotherapy (NACT) is strongly associated with a higher
curative resection rate and favorable outcomes for patients with gastric cancer (GC). We …
curative resection rate and favorable outcomes for patients with gastric cancer (GC). We …
[HTML][HTML] Perioperative tailored treatments for gastric cancer: times are changing
D Lavacchi, S Fancelli, E Buttitta, G Vannini… - International Journal of …, 2023 - mdpi.com
Resectable gastric or gastroesophageal (G/GEJ) cancer is a heterogeneous disease with no
defined molecularly based treatment strategy. Unfortunately, nearly half of patients …
defined molecularly based treatment strategy. Unfortunately, nearly half of patients …
Tumor Immunophenotyping‐Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer
JB Wang, QZ Qiu, QL Zheng, YJ Zhao, Y Xu… - Advanced …, 2023 - Wiley Online Library
The effectiveness of neoadjuvant immune checkpoint inhibitor (ICI) therapy is confirmed in
clinical trials; however, the patients suitable for receiving this therapy remain unspecified …
clinical trials; however, the patients suitable for receiving this therapy remain unspecified …